An analogous mutation, HER2‐C805S, has been reported at resistance to HER2 TKI therapy in HER2‐mutated NSCLC,269 which is assumed to affect the binding of HER2 TKIs. Here, ERBB2 is linked to non-small cell lung carcinoma.